July 2, 2018 Regulatory Developments
Here are the most recent health care related regulatory developments as published in the New Jersey Register on July 2, 2018:
On July 2, 2018, at 50 N.J.R. 1468(a), the State Board of Pharmacy issued a proposal to amend the regulations regarding the effective date for complying with Chapter 800 of the United States Pharmacopoeia/National Formulary (USP 800), which sets forth standards for compounding antineoplastic agents (i.e., anti-tumor) and other hazardous substances. The Board is, therefore, proposing to amend the effective date for pharmacies to meet the requirements of USP 800 from July 1, 2018, to the official (effective) date of General Chapter 800 which is currently December 1, 2019.
On July 2, 2018, at 50 N.J.R. 1494(a), the Department of Health issued a notice of readoption of N.J.A.C. 8:31B, Hospital Financial Reporting, which was scheduled to expire June 29, 2018. The readopted rules includes technical amendments to the existing rule and will be in effect for a period of seven years.
On July 2, 2018, at 50 N.J.R. 1500(a), the Department of Law and Public Safety, Division of Consumer Affairs issued a notice of adoption of amendments to the Prescription Monitoring Program. The program is now accessible to certified medical assistants, registered dental assistants and licensed mental health practitioners. The rule adoption gives the Division authority to review the PMP information submitted by a pharmacy permit holder. The rule adoption also amends recordkeeping requirements and names non-compliance with the PMP regulations as grounds for professional misconduct.